Adverse event, n (%) | Placebo (N=20) | FF/VI 400/25 μg (N=40) |
Any event | 10 (50) | 27 (68) |
Nasopharyngitis | 3 (15) | 7 (18) |
Headache | 1 (5) | 6 (15) |
Dizziness | 1 (5) | 2 (5) |
Oral candidiasis | 0 | 3 (8) |
Dysphonia | 0 | 2 (5) |
Chest pain | 1 (5) | 1 (3) |
Dry mouth | 1 (5) | 0 |
Dyspnoea | 1 (5) | 0 |
ECG abnormal | 1 (5) | 0 |
Erythema | 1 (5) | 0 |
Hyperhidrosis | 1 (5) | 0 |
Myalgia | 1 (5) | 0 |
Fever | 1 (5) | 0 |
Rash | 1 (5) | 0 |
Urinary tract infection | 1 (5) | 0 |
FF, fluticasone furoate; VI, vilanterol.